Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapy. Results of the thrombolysis and angioplasty in mycardial infaraction (TAMI) 8 pilot study
Angioplasty, Balloon, Coronary
Coronary Artery Disease
Profound inhibition of platelet aggregation after thrombolysis was associated with bleeding rates comparable to those in control patients and a low rate of recurrent ischemia. The combination of m7E3 Fab and rt-PA, heparin and aspirin appears to be a promising and safe combination that should be evaluated in further studies of patients with acute myocardial infarction.